anlotinib + bevacizumab + furmonertinib

This is a combination regimen consisting of three agents: **Anlotinib** is a multi-targeted small molecule tyrosine kinase inhibitor that inhibits angiogenesis and tumor cell proliferation by targeting receptors such as VEGFR, FGFR, PDGFR, and c-Kit. **Bevacizumab** is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. **Furmonertinib** is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with high selectivity for mutant EGFR, including T790M resistance mutations and exon 20 insertions. It has demonstrated efficacy in non-small cell lung cancer (NSCLC) patients with EGFR mutations[1][2][3][4][5]. This combination may be used in investigational settings for advanced or metastatic NSCLC harboring EGFR mutations.

Other names

anlotinib hydrochlorideAvastin (bevacizumab)Furmonertinib mesylate